Pneumonitis in Patients Receiving Thoracic Radiotherapy and Osimertinib: A Multi-Institutional Study

This publication has 22 references indexed in Scilit:

• Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non–small-cell Lung Cancer: LAURA Trial in Progress
  Clinical Lung Cancer, 2021
• Real-World Evaluation of Factors for Interstitial Lung Disease Incidence and Radiologic Characteristics in Patients With EGFR T790M–positive NSCLC Treated With Osimertinib in Japan
  Journal of Thoracic Oncology, 2020
• An especially high rate of radiation pneumonitis observed in patients treated with thoracic radiotherapy and simultaneous osimertinib
  Radiotherapy and Oncology, 2020
• Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer
  New England Journal of Medicine, 2020
• Osimertinib, a third‐generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real‐world efficacy and safety in advanced/recurrent non‐small cell lung carcinoma
  Thoracic Cancer, 2020
• Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC
  New England Journal of Medicine, 2020
• Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
  New England Journal of Medicine, 2018
• Radiation Pneumonitis in Patients with Non–Small-Cell Lung Cancer Treated with Erlotinib Concurrent with Thoracic Radiotherapy
  Journal of Thoracic Oncology, 2014
• Preliminary analysis of the risk factors for radiation pneumonitis in patients with non- small-cell lung cancer treated with concurrent erlotinib and thoracic radiotherapy
  OncoTargets and Therapy, 2014
• Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC)
  International Journal of Radiation Oncology - Biology - Physics (IJROBP), 1995